Comment
doi: 10.1136/annrheumdis-2020-218075.
Epub 2020 Jun 26.
Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab
Affiliations
- PMID: 32591357
- DOI: 10.1136/annrheumdis-2020-218075
Item in Clipboard
Comment
Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab
Ann Rheum Dis.
2021 May.
No abstract available
Keywords: B-Lymphocytes; arthritis, rheumatoid; rituximab.
Conflict of interest statement
Competing interests: None declared.
Comment in
-
Response to: 'Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab' by Schulze-Koops et al.Ann Rheum Dis. 2021 May;80(5):e68. doi: 10.1136/annrheumdis-2020-218148. Epub 2020 Jun 26. Ann Rheum Dis. 2021. PMID: 32591359 No abstract available.
Comment on
-
Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive _targeted therapies.Ann Rheum Dis. 2020 May;79(5):667-668. doi: 10.1136/annrheumdis-2020-217424. Epub 2020 Apr 2. Ann Rheum Dis. 2020. PMID: 32241793 Free PMC article. No abstract available.
Similar articles
-
Response to: 'Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab' by Schulze-Koops et al.Ann Rheum Dis. 2021 May;80(5):e68. doi: 10.1136/annrheumdis-2020-218148. Epub 2020 Jun 26. Ann Rheum Dis. 2021. PMID: 32591359 No abstract available.
-
Presence of specific T cell response after SARS-CoV-2 vaccination in rheumatoid arthritis patients receiving rituximab.Immunol Res. 2021 Aug;69(4):309-311. doi: 10.1007/s12026-021-09212-5. Epub 2021 Jul 29. Immunol Res. 2021. PMID: 34324159 Free PMC article. No abstract available.
-
Prolonged Coronavirus Disease 2019 in a Patient With Rheumatoid Arthritis on Rituximab Therapy.J Infect Dis. 2021 Aug 2;224(3):557-559. doi: 10.1093/infdis/jiab248. J Infect Dis. 2021. PMID: 33964153 Free PMC article. No abstract available.
-
Efficacy and safety of rituximab in rheumatic diseases.Wien Med Wochenschr. 2015 Jan;165(1-2):28-35. doi: 10.1007/s10354-014-0331-8. Epub 2015 Jan 21. Wien Med Wochenschr. 2015. PMID: 25676699 Review.
-
Severe infection in patients with rheumatoid arthritis taking anakinra, rituximab, or abatacept: a systematic review of observational studies.Rev Bras Reumatol Engl Ed. 2016 Nov-Dec;56(6):543-550. doi: 10.1016/j.rbre.2016.10.001. Epub 2016 Oct 27. Rev Bras Reumatol Engl Ed. 2016. PMID: 27914602 Review. English, Portuguese.
Cited by
-
Impaired Neutralizing Antibody Activity against B.1.617.2 (Delta) after Anti-SARS-CoV-2 Vaccination in Patients Receiving Anti-CD20 Therapy.J Clin Med. 2022 Mar 21;11(6):1739. doi: 10.3390/jcm11061739. J Clin Med. 2022. PMID: 35330069 Free PMC article.
-
Progression of COVID-19 in a Patient on Anti-CD20 Antibody Treatment: Case Report and Literature Review.Case Rep Infect Dis. 2022 Feb 25;2022:8712424. doi: 10.1155/2022/8712424. eCollection 2022. Case Rep Infect Dis. 2022. PMID: 35251723 Free PMC article.
-
Rheumatic Musculoskeletal Diseases and COVID-19 A Review of the First 6 Months of the Pandemic.Front Med (Lausanne). 2020 Oct 9;7:562142. doi: 10.3389/fmed.2020.562142. eCollection 2020. Front Med (Lausanne). 2020. PMID: 33154972 Free PMC article. Review.
-
Prolonged SARS-CoV-2 Infection With Common Features in Two Patients Receiving Anti-CD20 Therapy.In Vivo. 2023 Jan-Feb;37(1):461-467. doi: 10.21873/invivo.13100. In Vivo. 2023. PMID: 36593037 Free PMC article.
-
Promising Efficacy of a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients Treated with Anti-CD20 Antibody Who Failed 2-Dose Vaccination.Vaccines (Basel). 2022 Jun 17;10(6):965. doi: 10.3390/vaccines10060965. Vaccines (Basel). 2022. PMID: 35746573 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
